About the PDMP
The Prescription Drug Monitoring Program (PDMP) aims to improve the District’s ability to identify and reduce diversion of prescription drugs in an efficient and cost effective manner that will not impede the appropriate medical utilization of controlled substances. The PDMP also aims to enhance patient care by providing prescription monitoring information that will assure legitimate use of controlled substances in health care, including palliative care, research and other medical and pharmacological uses.
Log in to the DC PDMP Here
*NEW LAW* MANDATORY PDMP QUERY: Mandatory query is now in effect in the District of Columbia. DC Law 23-251. Prescription Drug Monitoring Program Query and Omnibus Health Amendments Act of 2020 became effective on March 16, 2021. The law requires prescribers and dispensers to query the PDMP:
- Prior to prescribing or dispensing an opioid or benzodiazepine for more than seven consecutive days, and
- Every ninety days thereafter while the course of treatment or therapy continues, or
- Prior to dispensing another refill after ninety days.
The law is available here: https://code.dccouncil.us/dc/council/laws/23-251.html.
DC PDMP WEBINAR ON MANDATORY PDMP QUERY: The DC PDMP presents an informational webinar of the Prescription Drug Monitoring Program Query Amendment Act of 2020. Learn about the requirements of the Act as outlined above, how to perform a patient query, and other DC PDMP features.
To access the pre-recorded webinar, click here.
MANDATORY PDMP REGISTRATION: All licensed prescribers and dispensers must register for the DC Prescription Drug Monitoring Program. Read the notices to practitioners or FAQs about mandatory registration for full details.
For dispensers: As of June 7, 2019, gabapentin is a covered substance for the DC PDMP. Dispensers are required to report dispensations of gabapentin to the DC PDMP.
*NEW RESOURCE* Safe Opioid Prescribing Pocket Guide This DIGITAL guide provides a number of resources to providers, including: CDC guidelines for safe opioid prescribing, a Morphine Milligram Equivalent (MME) conversion chart, a checklist for prescribing opioids for chronic pain, Medication Assisted Therapy (MAT) resources, and additional resources for providers and patients.
If you would like PRINTED copies of the Pocket Guide, complete the Safe Opioid Prescribing pocket guide order form. A member of the DC PDMP staff will contact you to confirm your order.
PMP AWARXE™ PMP AWARXE™ is the software platform that providers use to access the PDMP.
NarxCare The NarxCare platform allows providers and dispensers to view patient health history and patient risk scores. NarxCare's analytics tools help providers and dispensers make decisions to increase patient safety and reduce the risk of prescription drug misuse and overdose.
Gateway Integration The DC PDMP provides the option to all Health Care Entities (HCE) in the District of Columbia to integrate DC PDMP data into their clinical workflow. DC Health covers the licensing fees associated with the integration service for every health care entity in the District of Columbia that elects to connect its Electronic Health Records (EHR), Health Information Exchange (HIE), or Pharmacy Dispensing System to the PMP Gateway.
PDMP Advisory Committee The DC PDMP Advisory Comittee is a multisector committee made up of 7 members.The committee's goal is to make recommendations to DC Health's director regarding PDMP best practice, regulatory and legislative updates, education and outreach to prescribers and dispensers, and program enhancements.
The District of Columbia Prescription Drug Monitoring Program Advisory Committee
will hold a public meeting on:
Tuesday, August 17, 2021 from 10am--11:30am
via WebEx. WebEx login information will be posted when available.
Additional Resources
- Prescription Drug Monitoring Program Law
- Prescription Drug Monitoring Program Final Rulemaking
- Notices
- Frequently Asked Questions
- Forms
- Annual Report
All questions and press inquiries regarding the Prescription Drug Monitoring Program must be submitted in writing. Interested parties may send inquiries by email to [email protected] or by regular mail to:
Prescription Drug Monitoring Program
Health Regulation and Licensing Administration
899 N. Capitol Street, NE
2nd Floor
Washington, DC 20002